Mrna

Health
Personalized mRNA Cancer Vaccines in 2026: Where the Melanoma Trials Stand
A personalized mRNA vaccine plus Keytruda cut melanoma recurrence risk by 42% in a 2026 Phase 3 trial, but it is not yet FDA-approved. Here is how it works.
05 Aug, 2026·3 mins read